Pharmaceuticals News and Research

RSS

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.

5 Aug 2011

First Edition: August 5, 2011

In the news today... The cost of premiums for Medicare's prescription drug program won't rise in 2012. Meanwhile, Medicare data reveal a gap in hospital performance and perception.

5 Aug 2011

Study sheds light on new type of catalytic site where oxidation catalysis occurs

Mention catalyst and most people will think of the catalytic converter, an emissions control device in the exhaust system of automobiles that reduces pollution.

5 Aug 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.

5 Aug 2011

Health Affairs report describes ground-breaking effort that aims to prevent opioid abuse

Fatal overdoses involving prescribed opioids tripled in the United States between 1999 and 2006, climbing to almost 14,000 deaths annually-more than cocaine and heroin overdoses combined. Hospitalizations and emergency room visits related to prescription opioid pain medicines such as oxycodone and hydrocodone also increased dramatically in the same period.

5 Aug 2011

U.S. physicians spend more time, money for interaction with health plans than Canadian doctors

Physicians in the United States spend nearly four times as much dealing with health insurers and payers compared with doctors in Canada. Most of the difference stems from the fact that Canadian physicians deal with a single payer, in contrast to the multiple payers in the United States.

5 Aug 2011

PharmOut creates online database of Good Manufacturing Practice guidelines

For manufacturers who must comply with current Good Manufacturing Practice (GMP), keeping track of the latest guidelines can be time consuming and difficult. This task is considerably more complex if the manufacturer exports to multiple countries, each with their own GMP requirements.

5 Aug 2011

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.

5 Aug 2011

OncoGenex second quarter revenue increases to $1.9 million

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

5 Aug 2011

Abiomed first quarter fiscal 2012 revenue up 25% to $27.4 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2012 revenue of $27.4 million, up 25% compared to revenue of $22.0 million in the same period of fiscal 2011.

4 Aug 2011

Valeant second quarter total revenue increases to record $609.4 million

Valeant Pharmaceuticals International, Inc. announces second quarter financial results for 2011.

4 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Columbia Laboratories second quarter total net revenues increase to $19.2 million

Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.

4 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

UH undergraduates seek solutions to many maladies like diabetes, Alzheimer's

Students from a variety of majors are devoting their summers to serious research at the University of Houston (UH), seeking eventual solutions to many serious maladies that include Alzheimer's, high blood pressure and cholesterol, diabetes, alcoholism and anxiety.

4 Aug 2011

U.S. PTO to reissue two patents for Dey Pharma's Perforomist Inhalation Solution

Dey Pharma L.P., a subsidiary of Mylan Inc., today announced that the U.S. Patent and Trademark Office intends to reissue both of the patents related to Perforomist Inhalation Solution 20 mcg/2mL vial that had been placed into reexamination by Sepracor, now known as Sunovion Pharmaceuticals.

4 Aug 2011

SynCo Bio commences release of drug products after expansion of Class A zone

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.

4 Aug 2011

Pharmaceuticals News and Research

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Idera second quarter net loss increases to $6.3 million

Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients

First Edition: August 5, 2011

Study sheds light on new type of catalytic site where oxidation catalysis occurs

World RNA Interference market will be worth $4 billion by 2017: New report

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Health Affairs report describes ground-breaking effort that aims to prevent opioid abuse

U.S. physicians spend more time, money for interaction with health plans than Canadian doctors

PharmOut creates online database of Good Manufacturing Practice guidelines

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

OncoGenex second quarter revenue increases to $1.9 million

Abiomed first quarter fiscal 2012 revenue up 25% to $27.4 million

Valeant second quarter total revenue increases to record $609.4 million

Micromet second quarter total revenues increase to $7.1 million

Columbia Laboratories second quarter total net revenues increase to $19.2 million

BioCryst second quarter total revenues decrease to $3.7 million

UH undergraduates seek solutions to many maladies like diabetes, Alzheimer's

U.S. PTO to reissue two patents for Dey Pharma's Perforomist Inhalation Solution

SynCo Bio commences release of drug products after expansion of Class A zone

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence